What is the main business of Krotex Pharm?

The main business activity of Krotex Pharm focuses on manufacture of pharmaceutical preparations.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on October 30, 2012.

Where is the headquarters located?

The headquarters is located at: ul. Szczęsna 26, 02-454 Warszawa.

Who is on the management board?

The management board consists of: Maksymilian Benedykt Jaromski (President of the Management Board).

What is the share capital?

The share capital of the company is PLN 5,000 (approx. $1,351).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2022 to December 31, 2022.

How much revenue was generated?

In 2022, the company generated total revenue of USD 40,377, representing a decrease of 1.0% compared to 2021.

No, in 2022 the company was not profitable, reporting a net loss of USD 1,076.

Krotex Pharmsp. z o.o.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2012-10-30

Share capital

5,000.00 PLN

Registered address

ul. Szczęsna 26, 02-454 Warszawa, Poland

Financials

Revenue history (in k)

Filing timeliness

No financial statement for 2023 – the filing deadline has passed. 2 of 5 financial statements were filed late (the longest delay 476 days for 2021).

2023not filed
202203/11/2023
202103/11/2023
202029/06/2021
201922/07/2020
201807/06/2019

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2022.

Industry · Manufacture of pharmaceutical preparations204 / 258

Top 79%

Division · Manufacture of basic pharmaceutical products and pharmaceutical preparations253 / 330

Top 77%

Sector · Manufacturing27,482 / 33,751

Top 81%

Voivodeship · Mazowieckie95,225 / 142,048

Top 67%

Country · Poland342,097 / 495,934

Top 69%

Results vs industry

Revenue

This companyUSD 40.38kMedianUSD 919.05kAverageUSD 25.83m

Net profit

This companyUSD -1.08kMedianUSD 14.92kAverageUSD 2.77m

Operating costs

This companyUSD 41.04kMedianUSD 873.06kAverageUSD 21.42m

Assets

This companyUSD 19.88kMedianUSD 897.46kAverageUSD 31.52m

Industry

Authorized Representatives

Maksymilian Benedykt Jaromskiage 33 – President of the Management Board

Manner of representation

In the case of a multi-member management board, the company is represented by the President of the Management Board acting independently, or by two members of the management board acting jointly.

Ownership

Owner	Shares	Share value	Stake
Maria Scholastyka Chmielewskaage 33	10	$135.06	10%
Wiktoria Elżbieta Jaromska-Gumkowskaage 37	10	$135.06	10%
Maksymilian Benedykt Jaromskiage 33	10	$135.06	10%
Elżbieta Helena Murawskaage 88	70	$945.43	70%

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2013-02-22.

mBank
91 1140 1977 0000 5994 3100 1003
mBank
48 1140 1977 0000 5994 3100 1001
mBank
21 1140 1977 0000 5994 3100 1002

Debt

No entries in the National Debtors Register (KRZ).

Public aid

No public aid cases recorded in the last 10 years.

Competitors

Name	Revenue	Website
STEM Cells SpinS.A.	$287,714.76	stemcellsspin.com.pl
F1 PharmaS.A.	$272,113.66	f1pharma.pl
Ti-Comsp. z o.o.	$157,549.77	ticomglobal.com
LideoS.A.	$95,067.91	lideo.tech
Munar PharmaS.A.	$85,649.72	munar.pl
Ampliconsp. z o.o.	$48,330.99	amplicon.pl
Xenira Pharmaceuticalssp. z o.o.	$26,670.82	xenirapharma.com

Change history

Date	Event
2026-09-03	Address change (Dostępna 56, 01-490, Warszawa → Ul. Szczęsna 26, 02-454, Warszawa)
2016-02-18	PKD change (Removed: 28 codes)
2013-02-26	Name change (Eme → Krotex Pharm)
2012-10-30	Entered in the register

FAQ

Last updated: 2026-09-04